The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Open accessAbstract
Purpose: Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis. Patients and Methods: We determined the correlation between presence of MYC and BCL2 proteins by immunohistochemistry (IHC) with survival in two independent cohorts of patients with DLBCL treated with R-CHOP. We further determined if MYC protein expression correlated with high MYC mRNA and/or presence of MYC translocation. Results: In the training cohort (n = 167), MYC and BCL2 proteins were detected in 29% and 44% of patients, respectively. Concurrent expression (MYC positive/BCL2 positive) was present in 21% of patients. MYC protein correlated with presence of high MYC mRNA and MYC translocation (both P < .001), but the latter was less frequent (both 11%). MYC protein expression was only associated with inferior overall and progression-free survival when BCL2 protein was coexpressed (P < .001). Importantly, the poor prognostic effect of MYC positive/BCL2 positive was validated in an independent cohort of 140 patients with DLBCL and remained significant (P < .05) after adjusting for presence of high-risk features in a multivariable model that included elevated international prognostic index score, activated B-cell molecular subtype, and presence of concurrent MYC and BCL2 translocations. Conclusion: Assessment of MYC and BCL2 expression by IHC represents a robust, rapid, and inexpensive approach to risk-stratify patients with DLBCL at diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationCamp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Hans, C. P. (2004) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 3,703
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D. L., Cory, S., & Adams, J. M. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,219
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Widespread microRNA repression by Myc contributes to tumorigenesis
Chang, T.-C., Yu, D., Lee, Y.-S., Wentzel, E. A., Arking, D. E., West, K. M., Dang, C. V., Thomas-Tikhonenko, A., & Mendell, J. T. (2008) · Nature Genetics · doi:10.1038/ng.2007.30 · Cited by 1,325
Wright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040
Self-citationMYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Molecular Diagnosis of Burkitt's Lymphoma
Dave, S. S., Fu, K., Wright, G. W., Lam, L. T., Kluin, P., Boerma, E.-J., Greiner, T. C., Weisenburger, D. D., Rosenwald, A., Ott, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055759 · Cited by 897
Self-citationc-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., & Wahl, G. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00520-8 · Cited by 876
Aukema, S. M., Siebert, R., Schuuring, E., van Imhoff, G. W., Kluin-Nelemans, H. C., Boerma, E.-J., & Kluin, P. M. (2011) · Blood · doi:10.1182/blood-2010-09-297879 · Cited by 678
Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660
Self-citationChoi, W. W. L., Weisenburger, D. D., Greiner, T. C., Piris, M. A., Banham, A. H., Delabie, J., Braziel, R. M., Geng, H., Iqbal, J., Lenz, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0113 · Cited by 642
Self-citationLymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M. J. S., Siebert, R., Kuruvilla, J., Klasa, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-212191 · Cited by 587
Self-citationREporting recommendations for tumor MARKer prognostic studies (REMARK)
for the Statistics Subcommittee of the NCI—EORTC Working Group on Cancer Diagnostics (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0252 · Cited by 561
Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E., & Jack, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3947 · Cited by 552
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Self-citationMounier, N. (2003) · Blood · doi:10.1182/blood-2002-11-3442 · Cited by 513
Hoffman, B., & Liebermann, D. A. (2008) · Oncogene · doi:10.1038/onc.2008.312 · Cited by 488
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
Gurel, B., Iwata, T., M Koh, C., Jenkins, R. B., Lan, F., Van Dang, C., Hicks, J. L., Morgan, J., Cornish, T. C., Sutcliffe, S., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.111 · Cited by 441
BCL2 translocation frequency rises with age in humans
Liu, Y., Hernandez, A. M., Shibata, D., & Cortopassi, G. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8910 · Cited by 358
Gutiérrez, G., Cardesa‐Salzmann, T. M., Climent, F., González-Barca, E. M., Mercadal, S., Mate, J. L., Sancho, J., Arenillas, L., Serrano, S., Escoda, L., et al. (2011) · Blood · doi:10.1182/blood-2010-12-322362 · Cited by 334
Self-citationIqbal, J., Neppalli, V. T., Wright, G., Dave, B. J., Horsman, D. E., Rosenwald, A., Lynch, J., Hans, C. P., Weisenburger, D. D., Greiner, T. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4264 · Cited by 298
Self-citationIqbal, J., Sanger, W. G., Horsman, D. E., Rosenwald, A., Pickering, D. L., Dave, B., Dave, S., Xiao, L., Cao, K., Zhu, Q., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63284-1 · Cited by 279
Self-citationWinter, J. N. (2006) · Blood · doi:10.1182/blood-2005-10-4222 · Cited by 265
Mead, G. M., Barrans, S. L., Qian, W., Walewski, J., Radford, J. A., Wolf, M., Clawson, S. M., Stenning, S. P., Yule, C. L., & Jack, A. S. (2008) · Blood · doi:10.1182/blood-2008-03-145128 · Cited by 215
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Klapper, W., Kreuz, M., Kohler, C. W., Burkhardt, B., Szczepanowski, M., Salaverria, I., Hummel, M., Loeffler, M., Pellissery, S., Woessmann, W., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388470 · Cited by 191
Salles, G., de Jong, D., Xie, W., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Calaminici, M., Sander, B., Thorns, C., et al. (2011) · Blood · doi:10.1182/blood-2011-04-345256 · Cited by 190
Self-citationIqbal, J., Meyer, P. N., Smith, L. M., Johnson, N. A., Vose, J. M., Greiner, T. C., Connors, J. M., Staudt, L. M., Rimsza, L., Jaffe, E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0267 · Cited by 176
Self-citationImmunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas
Kluk, M. J., Chapuy, B., Sinha, P., Roy, A., Cin, P. D., Neuberg, D. S., Monti, S., Pinkus, G. S., Shipp, M. A., & Rodig, S. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033813 · Cited by 162
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
Mason, K. D., Vandenberg, C. J., Scott, C. L., Wei, A. H., Cory, S., Huang, D. C. S., & Roberts, A. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809957105 · Cited by 140
Malignant pirates of the immune system
Rui, L., Schmitz, R., Ceribelli, M., & Staudt, L. M. (2011) · Nature Immunology · doi:10.1038/ni.2094 · Cited by 140
Self-citationRimsza, L. M., LeBlanc, M. L., Unger, J. M., Miller, T. P., Grogan, T. M., Persky, D. O., Martel, R. R., Sabalos, C. M., Seligmann, B. E., Braziel, R. M., et al. (2008) · Blood · doi:10.1182/blood-2008-02-137372 · Cited by 139
Self-citationBcl-2 Mediates Chemoresistance in Matched Pairs of Primary Eμ-myc Lymphomas in Vivo
Schmitt, C. A., & Lowe, S. W. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0372 · Cited by 104
Tzankov, A., Zlobec, I., Went, P., Robl, H., Hoeller, S., & Dirnhofer, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903370338 · Cited by 96
Myc increases self-renewal in neural progenitor cells through Miz-1
Kerosuo, L., Piltti, K. M., Fox, H., Angers‐Loustau, A., Häyry, V., Eilers, M., Sariola, H. V., & Wartiovaara, K. (2008) · Journal of Cell Science · doi:10.1242/jcs.024802 · Cited by 73
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction
Choi, P. S., van Riggelen, J., Gentles, A. J., Bachireddy, P., Rakhra, K., Adam, S. J., Plevritis, S. K., & Felsher, D. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107303108 · Cited by 43
Cited by
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Self-citationSehn, L. H., & Salles, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027612 · Cited by 1,175
Self-citationGenetic and functional drivers of diffuse large B cell lymphoma
Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.027 · Cited by 1,104
Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., Walewski, J., André, M., Johnson, P. W., Pfreundschuh, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv304 · Cited by 930
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Self-citation
Metadata
- Authors
- Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., Chan, W. C., Iqbal, J., Meyer, P. N., Lenz, G., Wright, G., Rimsza, L. M., Valentino, C., Brunhoeber, P., Grogan, T. M., Braziel, R. M., Cook, J. R., Tubbs, R. R., Weisenburger, D. D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E. S., Staudt, L. M., & Gascoyne, R. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-10-01
- Volume
- 30
- Issue
- 28
- Pages
- 3452-3459
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159862107
- Cited by
- 975
- References
- 43
- FWCI
- 46.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.